Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
BioVie Inc (BIVI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.21-9.70%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BIVI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful capital raises to fund clinical development | A primary condition in BioVie Inc's published investment case. The stated target is Raise at least $5M in new capital within the next 12 months. | Intact | capital raises fall below $5M or fail to close within 12 months | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The thesis remains at a watch stage: management has reported promising Phase 2 results, but the evidence snapshot gives no revenue or profit data to show commercial progress.
The snapshot provides no valuation or market-expectations data, so whether BIVI looks cheap or expensive versus peers, or how much clinical success is already assumed, cannot be assessed. The business is loss-making, which makes valuation especially hard to judge from the available evidence.
In the near term, earnings risk is elevated, with a history of recent misses and weaker performance than its industry cohort. For the multi-year thesis, the key fundamental evidence is the Phase 2 SUNRISE-PD report: bezisterim improved clinical symptoms and biomarkers, with statistically significant composite endpoint improvements; further development remains to be demonstrated.
The thesis hinges on whether the Parkinson’s results can be confirmed and translated into further clinical progress. Near-term sector conditions may also matter: stronger results from healthcare bellwethers could support the sector backdrop, while misses or weaker guidance could remove that tailwind. A weakening jobs trend adds another risk flagged in the evidence.
Over the next 1 to 3 years, BIVI remains a high-risk clinical story with an encouraging early signal but limited financial evidence and meaningful execution uncertainty. The available snapshot does not establish how much success is already reflected in valuation. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company has stable management and no recent market stress. |
| Intact |
| major management departures or instability within 12 months |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advancement toward generating revenue | A primary condition in BioVie Inc's published investment case. The stated target is Achieve first revenue generation by FY27 or show clinical progress enabling revenue. | Intact | no revenue or clinical progress by FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Unavailable → $-0.57 · observed estimates
FY2028 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | Unavailable | Unavailable | 0 / 0 |
| 2026-07-25 | Unavailable | Unavailable | 0 / 0 |
| 2026-07-26 | $-0.57 | Unavailable | 1 / 0 |
| 2026-07-27 | $-0.57 | Unavailable | 1 / 0 |
| 2026-07-28 | $-0.57 | Unavailable | 1 / 0 |
| 2026-07-29 | $-0.57 | Unavailable | 1 / 0 |
| 2026-07-30 | $-0.57 | Unavailable | 1 / 0 |
| 2026-07-31 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-01 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-02 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-03 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-04 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-05 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-06 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-07 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-08 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-09 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-10 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-11 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-12 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-13 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-14 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-15 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-16 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-17 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-18 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-19 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-20 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-21 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-22 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-23 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-24 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-25 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-26 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-27 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-28 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-29 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-30 | $-0.57 | Unavailable | 1 / 0 |
| 2026-08-31 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-01 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-02 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-03 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-04 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-05 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-06 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-07 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-08 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-09 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-10 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-11 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-12 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-13 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-14 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-15 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-16 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-17 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-18 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-19 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-20 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-21 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-22 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-23 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-24 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-25 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-26 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-27 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-28 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-29 | $-0.57 | Unavailable | 1 / 0 |
| 2026-09-30 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-01 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-02 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-03 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-04 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-05 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-06 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-07 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-08 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-09 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-10 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-11 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-12 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-13 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-14 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-15 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-16 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-17 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-18 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-19 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-20 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-21 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-22 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-23 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-24 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-25 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-26 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-27 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-28 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-29 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-30 | $-0.57 | Unavailable | 1 / 0 |
| 2026-10-31 | $-0.57 | Unavailable | 1 / 0 |
| 2026-11-01 | $-0.57 | Unavailable | 1 / 0 |
| 2026-11-02 | $-0.57 | Unavailable | 1 / 0 |
| 2026-11-03 | $-0.57 | Unavailable | 1 / 0 |
| 2026-11-04 | $-0.57 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.